Stuttgart - Delayed Quote EUR

Incyte Corp (ICY.SG)

Compare
66.72
+0.76
+(1.15%)
At close: 9:54:26 PM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
4,241,217.00
4,241,217.00
3,695,649.00
3,394,635.00
2,986,267.00
Cost of Revenue
312,100.00
312,100.00
255,000.00
207,000.00
150,991.00
Gross Profit
3,929,117.00
3,929,117.00
3,440,649.00
3,187,635.00
2,835,276.00
Operating Expense
3,827,823.00
3,827,823.00
2,790,939.00
2,596,009.00
2,234,758.00
Operating Income
101,294.00
101,294.00
649,710.00
591,626.00
600,518.00
Net Non Operating Interest Income Expense
126,430.00
126,430.00
155,863.00
37,785.00
8,739.00
Other Income Expense
88,831.00
88,831.00
28,625.00
-100,258.00
-38,813.00
Pretax Income
316,630.00
316,630.00
834,215.00
529,116.00
570,444.00
Tax Provision
284,015.00
284,015.00
236,616.00
188,456.00
-378,137.00
Net Income Common Stockholders
32,615.00
32,615.00
597,599.00
340,660.00
948,581.00
Diluted NI Available to Com Stockholders
32,615.00
32,615.00
597,599.00
340,660.00
948,581.00
Basic EPS
0.10
0.16
2.67
1.53
4.30
Diluted EPS
0.09
0.15
2.65
1.52
4.27
Basic Average Shares
214,879.25
207,110.00
223,628.00
222,004.00
220,428.00
Diluted Average Shares
215,433.25
210,530.00
225,928.00
223,958.00
222,074.00
Total Operating Income as Reported
61,366.00
61,366.00
620,525.00
579,440.00
585,777.00
Total Expenses
4,139,923.00
4,139,923.00
3,045,939.00
2,803,009.00
2,385,749.00
Net Income from Continuing & Discontinued Operation
32,615.00
32,615.00
597,599.00
340,660.00
948,581.00
Normalized Income
-27,442.38
-27,442.38
587,080.24
404,891.92
976,914.49
Interest Income
128,710.00
128,710.00
158,414.00
40,451.00
10,647.00
Interest Expense
2,280.00
2,280.00
2,551.00
2,666.00
1,908.00
Net Interest Income
126,430.00
126,430.00
155,863.00
37,785.00
8,739.00
EBIT
318,910.00
318,910.00
836,766.00
531,782.00
572,352.00
EBITDA
408,158.00
408,158.00
919,426.00
599,637.00
630,196.00
Reconciled Cost of Revenue
312,100.00
312,100.00
255,000.00
207,000.00
150,991.00
Reconciled Depreciation
89,248.00
89,248.00
82,660.00
67,855.00
57,844.00
Net Income from Continuing Operation Net Minority Interest
32,615.00
32,615.00
597,599.00
340,660.00
948,581.00
Total Unusual Items Excluding Goodwill
76,022.00
76,022.00
14,691.00
-99,739.00
-38,813.00
Total Unusual Items
76,022.00
76,022.00
14,691.00
-99,739.00
-38,813.00
Normalized EBITDA
332,136.00
332,136.00
904,735.00
699,376.00
669,009.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
15,964.62
15,964.62
4,172.24
-35,507.08
-10,479.51
12/31/2021 - 12/28/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

6Y4.F Vicore Pharma Holding AB (publ)
0.7310
-2.14%
 
HQ1.MU Oruka Therapeutics Inc. R
11.20
+3.70%
 
8F8.SG SynAct Pharma AB
1.3460
-1.68%
 
REGN.MX Regeneron Pharmaceuticals, Inc.
13,757.24
+0.80%
 
22UA.DU BioNTech SE
112.70
+4.35%
 
PH4.F CStone Pharmaceuticals
0.3060
-2.55%
 
605116.SS Aurisco Pharmaceutical Co.,Ltd.
19.75
-2.08%
 
0WA2.IL Cellectis S.A.
1.5200
0.00%
 
ALGEN.PA genOway Société anonyme
3.5400
+2.31%
 
ANNX.ST Annexin Pharmaceuticals AB (publ)
0.3310
+0.61%